title: How does premenstrual dysphoric disorder relate to depression and anxiety disorders?
abstract: Premenstrual dysphoric disorder (PMDD) is a severe variant of premenstrual syndrome that afflicts approximately 5% of all women of fertile age. The hallmark of this condition is the surfacing of symptoms during the luteal phase of the menstrual cycle, and the disappearance of symptoms shortly after the onset of menstruation. Whereas many researchers have emphasized the similarities between PMDD and anxiety disorders, and in particular panic disorder, others have suggested that PMDD should be regarded as a variant of depression. Supporting both these notions, the treatment of choice for PMDD, the serotonin reuptake inhibitors (SRIs), is also first line of treatment for depression and for most anxiety disorders. In this review, the relationship between PMDD on the one hand, and anxiety and depression on the other, is being discussed. Our conclusion is that PMDD is neither a variant of depression nor an anxiety disorder, but a distinct diagnostic entity, with irritability and affect lability rather than depressed mood or anxiety as most characteristic features. The clinical profile of SRIs when used for PMDD, including a short onset of action, suggests that this effect is mediated by other serotonergic synapses than the antidepressant and anti-anxiety effects of these drugs. Although we hence suggest that PMDD should be regarded as a distinct entity, it should be emphasized that this disorder does display intriguing similarities with other conditions, and in particular with panic disorder, which should be the subject of further studies. Also, the possibility that there are subtypes of PMDD more closely related to depression, or anxiety disorders, than the most common form of the syndrome, should not be excluded.
authors.affiliation: Section of Psychiatry, Göteborg University, Göteborg, Sweden. mikael.landen@neuro.gu.se
authors.forename: Mikael
authors.initials: M
authors.lastname: Landén
authors.forename: Elias
authors.initials: E
authors.lastname: Eriksson
mesh_terms: D001007:Anxiety / Q000175:diagnosis* / Q000188:drug therapy; D001921:Brain / Q000378:metabolism; D003863:Depression / Q000175:diagnosis* / Q000188:drug therapy; D003907:Dexamethasone / Q000493:pharmacokinetics; D003937:Diagnosis, Differential; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004967:Estrogens / Q000378:metabolism; D005260:Female; D005938:Glucocorticoids / Q000493:pharmacokinetics; D006801:Humans; D008183:Luteal Phase / Q000378:metabolism; D011293:Premenstrual Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
chemical_list: D003907:Dexamethasone; D004967:Estrogens; D005938:Glucocorticoids; D017367:Selective Serotonin Reuptake Inhibitors